Harrow Announces Appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilance

Harrow announced the appointment of Mark Mannebach, PhD, RPh, as Head of Regulatory Affairs and Pharmacovigilance, responsible for overseeing and managing all regulatory related submissions and strategy related to the company’s portfolio of new and existing products. Dr. Mannebach’s 30-year career in the pharmaceutical industry, much of which was focused in ophthalmology, includes leadership roles in regulatory affairs, quality assurance, program management and pharmaceutical product development.

“Dr. Mannebach brings to Harrow decades of regulatory and clinical expertise and leadership—specifically in ophthalmology—that we believe will be invaluable as we continue to execute on our strategic plan to expand our branded ophthalmic product portfolio,” Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said in a company news release. “We believe Mark’s deep industry knowledge, extensive experience interfacing with U.S. regulatory agencies, and his long history of developing and implementing effective regulatory processes to comply with FDA guidelines and applicable federal laws, will greatly benefit Harrow as we launch Iheezo, leverage our recent product acquisitions, and pursue new product acquisition and development opportunities.”

Dr. Mannebach’s previous roles included serving as the Vice President of Global Regulatory Affairs at both Mallinckrodt Pharmaceuticals and then Santen Pharmaceuticals. Earlier in his career, Dr. Mannebach held roles of increasing responsibility at Sanofi, Pharmacia, Baxter, and Pfizer.